MedTrace Logo

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.

NCT01789099 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-12-16

No results posted yet for this study

Summary

In this study, up to 21 patients with lung cancer will receive UV1 (a therapeutic synthetic peptide vaccine) at different dose levels. The safety and tolerability of UV1 as well as immunological response will be assessed. The purpose of this study is to select a biological dose of peptides for further clinical trials. Study recruitment completed at 6 patients in every dose level.

The main study treatment phase of this study is completed and will be reported separately.

Follow-up is ongoing

Conditions

Interventions

BIOLOGICAL

UV1 synthetic peptide vaccine and GM-CSF

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • Ultimovacs ASA

    lead INDUSTRY

Principal Investigators

  • Paal F. Brunsvig, MD PhD · Oslo University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-08
Primary Completion
2016-02-29
Completion
2020-06-12

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01789099 on ClinicalTrials.gov